On June 10, the journal Nature Biotechnology published an article written by Cancer Commons founder Marty Tenenbaum. The piece addresses a previously published article that proposes a megafund approach to finance biomedical research. According to Dr. Tenenenbaum, the megafund approach will not only reduce risk for investors, but will also “slash the time, cost and risk of drug development by radically rethinking development processes, business models and organizational structures, and requiring the open sharing of data, knowledge and resources across portfolio projects. The resulting impact on productivity, risk and new therapeutic opportunities could potentially dwarf the returns from financial engineering.”
Read Dr. Tenenbaum’s article here: The Cancer Megafund: A Catalyst for Disruptive Innovation. Nature Biotechnology 31, 491-492 (2013) doi:10.1038/nbt.2605.